Kindred Biosciences (KIN) Tops Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. FIS
6. DUOL
7. ARM
8. SWKS
9. SPY
10. XYZ

Go back to Kindred Biosciences (KIN) Tops Q1 EPS by 1c

Kindred Biosciences Announces First Quarter 2016 Financial Results

May 5, 2016 8:32 AM EDT

SAN FRANCISCO, May 5, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2016 and provided updates on its programs.  

"We successfully advanced our lead product candidates in the first quarter. We look forward to reporting topline results for KIND-010, a transdermal gel for the management of weight loss in cats, by mid-year, as planned. Additionally, preparations for the commercial launch of Zimeta for fever in horses are on track, positioning... More

Kindred Biosciences Submits KIND-010 New Animal Drug Application Technical Section for Chemistry, Manufacturing, and Controls to FDA

May 4, 2016 4:02 PM EDT

SAN FRANCISCO, May 4, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Chemistry, Manufacturing, and Controls (CMC) technical section of the New Animal Drug Application for KIND-010. 

Richard Chin, M.D., President and CEO of KindredBio, stated, "We... More